Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06130475 · ClinicalTrials.gov registry record · NA
Oral Rehydration Solution in Healthy Adults
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT06130475: Completed NA study, sponsored by Abbott Nutrition.
NCT06130475 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06130475, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
This is a prospective, randomized, controlled, blinded, crossover study to evaluate the effects of an oral hydration solution.
Primary Outcome
Calculated Change in Plasma Volume
Interventions
- OTHER Water
- OTHER Oral Rehydration Solution (ORS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2024-03-15 |
| Est. Completion | 2024-12-16 |
| Phase | NA |
What the finished NCT06130475 record still lists
NCT06130475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Water is the first listed.
NCT06130475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06130475 about?
NCT06130475 is a clinical study titled "Oral Rehydration Solution in Healthy Adults". This is a prospective, randomized, controlled, blinded, crossover study to evaluate the effects of an oral hydration solution.
What is the current status of trial NCT06130475?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2024-03-15. Estimated completion is 2024-12-16.
What interventions are being tested in trial NCT06130475?
The interventions under investigation include: Water (OTHER), Oral Rehydration Solution (ORS) (OTHER).
Who is sponsoring clinical trial NCT06130475?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06130475's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI